Pure Sunfarms, Emerald’s 50%-owned joint venture in Delta, BC, consists of two adjacent 1.1 million square foot greenhouses. The first one is licensed, fully planted and estimated to exceed 75,000 kg of cannabis annually. Completion of the second greenhouse will conservatively double potential production capacity. Production costs are around 1$/gram. Emerald will purchase 40 % of the total production from PSF from 2019 through 2022.
Verdélite, Emerald’s wholly-owned 88,000 square feet indoor grow facility in Saint-Eustache, QC, is a Licensed Producer and has a Standard Processing license, allowing it to not only cultivate and sell cannabis flowers but package, extract, manufacture, synthesize, test and sell next-generation cannabis products. Verdélite is expected to grow high quality cannabis and will develop a broad spectrum of cannabis-based products.
Emerald Health Hemp Inc. was contracted to supply Emerald Health Therapeutics with 836 acres of hemp chaff biomass in 2018 and 1,200 acres in 2019. Hemp chaff is a low-cost source of cannabidiol (CBD) and the 270,000 kg of biomass to be yielded in 2019 will be rendered into approximately 3500 kg of 2% CBD extract.
Victoria, Emerald’s wholly-owned 10,000 square foot facility in Victoria, BC, includes a 2000 square foot indoor grow and a 6000 square foot packaging and extraction operation. Victoria is Emerald’s Medicinal Cannabis hub, where customer relations, packaging and distribution take place. Victoria’s R&D lab is focused on plant genetics, breeding and next generation cannabis products development.
Avalite, Emerald’s wholly-owned analytical testing laboratory, is a Licensed Dealer and authorized to import and export cannabis and cannabis oils for R&D, prepare any manipulation, formulation, dosage form, strength or package size of cannabis, including mixtures with other additives, controlled substances, and non-controlled substances – expanding possible research and product innovation opportunities.
Emerald Health Naturals, Emerald’s 51/49 joint venture with Emerald Health Bioceuticals has exclusive Canadian distribution rights of the award-winning Endo product line (PhytoCann® Complex) of non-cannabis endocannabinoid-supporting products that can be sold through natural health product channels. The unique branding opportunity introduce consumers to the benefits of endocannabinoid-supporting products with the Emerald name.
Factors R&D Technology, Inc, a division of Factors Group of Nutritional Companies Inc., signed a term sheet with Emerald to form a strategic alliance in which it will provide industrial manufacturing capable of processing up to 1 million kg of biomass annually and softgel production capacity of up to 600 million capsules per year.
Indena is a global leader in plant extraction and botanical & phytochemical R&D for the pharmaceutical, health food, and personal care industries. Indena licensed Emerald with exclusivity rights in Canada to use their cannabidiol (CBD) extraction technology, and contract manufacturing services for CBD extraction. Also, Emerald has obtained exclusive use of Indena’s proprietary Phytosome® technology to develop novel cannabinoid-based products with superior formulation and bioavailability.
Emerald Health Biotechnology Espana is a cannabis-industry-leading research organization which Emerald has contracted to elucidate the mechanism of action of proprietary formulations and dosage forms for product development. This collaboration can strengthen Emerald’s intellectual property portfolio and assist in establishing Emerald as a leader in the development of proprietary cannabis products for medical-use and improved adult-use products with more precise and consistent delivery and dosage.